Is Actinium Pharmaceuticals Inc (ATNM) overvalued? · rev $81.0K
Actinium Pharmaceuticals Inc (ATNM) is a biotechnology company listed on US.
This page asks whether Actinium Pharmaceuticals Inc (ATNM) looks expensive on cached numbers — not a short thesis.
Latest reported ATNM revenue for 2023-12-31 was $81.0K. Net income was -$48.8M. Revenue was down 92.1% from 2022-12-31 to 2023-12-31. ATNM currently screens at market cap $33.9M.
ATNM currently screens at market cap $33.9M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next ATNM 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the ATNM stock page for the full model, not this heading.
Not investment advice.